Siltuximab Receives CHMP Positive Opinion For Use In The Treatment Of Multicentric Castleman’s Disease, A Very Rare Blood Disorder
- EMEA Innovative Medicine
- Siltuximab Receives CHMP Positive Opinion For Multicentric Castleman’s Disease
Siltuximab Receives CHMP Positive Opinion For Multicentric Castleman’s Disease
- X (Twitter)
Copy link